Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Archives of Gynecology and Obstetrics
Published in: Archives of Gynecology and Obstetrics 3/2016

Open Access 01-03-2016 | Review

Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review

Authors: Werner Mendling, Ernst Rainer Weissenbacher, Stefan Gerber, Valdas Prasauskas, Philipp Grob

Published in: Archives of Gynecology and Obstetrics | Issue 3/2016

Login to get access

Abstract

Background

Vaginal infections are responsible for a large proportion of gynaecological outpatient visits. Those are bacterial vaginosis (BV), vulvovaginal candidosis (VVC), aerobic vaginitis (AV) associated with aerobic bacteria, and mixed infections. Usual treatments show similar acceptable short-term efficacy, but frequent recurrences and increasing microbial resistance are unsolved issues. Furthermore, vaginal infections are associated with a variety of serious adverse outcomes in pregnancy and generally have a major impact on quality of life. Identifying the correct therapy can be challenging for the clinician, particularly in mixed infections.

Findings

Dequalinium chloride (DQC) is an anti-microbial antiseptic agent with a broad bactericidal and fungicidal activity. Systemic absorption after vaginal application of DQC is very low and systemic effects negligible. Vaginal DQC (Fluomizin®vaginal tablets) has been shown to have equal clinical efficacy as clindamycin in the treatment of BV. Its broad antimicrobial activity makes it appropriate for the treatment of mixed vaginal infections and in case of uncertain diagnosis. Moreover, resistance of pathogens is unlikely due to its multiple mode of action, and vaginal DQC provides also a reduced risk for post-treatment vaginal infections.

Conclusions

Vaginal DQC (10 mg) as 6-day therapy offers a safe and effective option for empiric therapy of different vaginal infections in daily practice. This review summarizes the available and relevant pharmacological and clinical data for the therapy of vaginal infections with vaginal DQC and provides the rationale for its use in daily gynaecologic practice.
Literature
1.
Hickey RJ, Zhou X, Pierson JD, Ravel J, Forney LJ (2012) Understanding vaginal microbiome complexity from an ecological perspective. Transl Res 160(4):267–282PubMedCentralPubMedCrossRef
2.
Li J, McCormick J, Bocking A, Reid G (2012) Importance of vaginal microbes in reproductive health. Reprod Sci 19(3):235–242PubMedCrossRef
3.
4.
Forsum U, Holst E, Larsson PG, Vasquez A, Jakobsson T, Mattsby-Baltzer I (2005) Bacterial vaginosis–a microbiological and immunological enigma. APMIS 113(2):81–90PubMedCrossRef
5.
O’Brien RF (2005) Bacterial vaginosis: many questions–any answers? Curr Opin Pediatr 17(4):473–479PubMedCrossRef
6.
Swidsinski A, Mendling W, Loening-Baucke V, Ladhoff A, Swidsinski S, Hale LP et al (2005) Adherent biofilms in bacterial vaginosis. Obstet Gynecol 106(5 Pt 1):1013–1023PubMedCrossRef
7.
8.
9.
Redelinghuys MJ, Ehlers MM, Dreyer AW, Kock MM (2015) Normal flora and bacterial vaginosis in pregnancy: an overview. Crit Rev Microbiol 41(4):1–12CrossRef
10.
Donders GG, Van Calsteren K, Bellen G, Reybrouck R, Van den Bosch T, Riphagen I et al (2009) Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG 116(10):1315–1324PubMedCrossRef
11.
Donders GG, Vereecken A, Bosmans E, Dekeersmaecker A, Salembier G, Spitz B (2002) Definition of a type of abnormal vaginal flora that is distinct from bacterial vaginosis: aerobic vaginitis. Brit J Obstet Gynecol 109:34–43CrossRef
12.
Gardner HL (1968) Desquamative inflammatory vaginitis: a newly defined entity. Am J Obstet Gynecol 102(8):1102–1105PubMed
13.
Sobel JD, Reichman O, Misra D, Yoo W (2011) Prognosis and treatment of desquamative inflammatory vaginitis. Obstet Gynecol 117(4):850–855PubMedCrossRef
14.
Sobel JD, Subramanian C, Foxman B, Fairfax M, Gygax SE (2013) Mixed vaginitis-more than coinfection and with therapeutic implications. Curr Infect Dis Rep 15(2):104–108PubMedCrossRef
15.
Donders GG, Zodzika J, Rezeberga D (2014) Treatment of bacterial vaginosis: what we have and what we miss. Expert Opin Pharmacother 15(5):645–657PubMedCrossRef
16.
Powell AM, Nyirjesy P (2014) Recurrent vulvovaginitis. Best Pract Res Clin Obstet Gynaecol 28(7):967–976PubMedCrossRef
17.
Barbes C, Boris S (1999) Potential role of lactobacilli as prophylactic agents against genital pathogens. AIDS Patient Care STDS 13(12):747–751PubMedCrossRef
18.
19.
Reid G, Bruce AW, McGroarty JA, Cheng K-J, Costerton JW (1990) Is there a role for lactobacilli in prevention of urogenital and intestinal infections? Clin Microbiol Rev 3(4):335–344PubMedCentralPubMed
20.
Schwebke JR (2009) New concepts in the etiology of bacterial vaginosis. Curr Infect Dis Rep 11(2):143–147PubMedCrossRef
21.
22.
Sobel JD (2009) Antibiotic consideration in bacterial vaginosis. Curr Infect Dis Rep 11(6):471–475PubMedCrossRef
23.
24.
Larsson PG (1992) Treatment of bacterial vaginosis. Int J STD AIDS 3(4):239–247PubMed
25.
26.
Petersen EE, Weissenbacher ER, Hengst P, Spitzbart H, Weise W, Wolff F et al (2002) Local treatment of vaginal infections of varying etiology with dequalinium chloride or povidone iodine. A randomised, double-blind, active-controlled, multicentric clinical study. Arzneimittelforschung 52(9):706–715PubMed
27.
28.
Strecker M, Kokemohr H, Teucher T, Schmitz H (1993) Antiseptika gegen Vulvovaginitiden. TW Gynäkologie 6:409–412
29.
Sweet RL, Gibbs RS (1995) Infectious vulvovaginitis. Infectious Diseases of the Female Genital Tract, 3rd edn. Williams & Wilkins, Baltimore, pp 341–362
30.
Mendling W, Brasch J (2012) Guideline vulvovaginal candidosis (2010) of the German Society for Gynecology and Obstetrics, the Working Group for Infections and Infectimmunology in Gynecology and Obstetrics, the German Society of Dermatology, the Board of German Dermatologists and the German Speaking Mycological Society. Mycoses 55(Suppl 3):1–13PubMedCrossRef
31.
32.
Weissenbacher ER, Donders G, Unzeitig V, de Martinez TB, Gerber S, Halaska M et al (2012) A comparison of dequalinium chloride vaginal tablets (Fluomizin(R)) and clindamycin vaginal cream in the treatment of bacterial vaginosis: a single-blind, randomized clinical trial of efficacy and safety. Gynecol Obstet Invest 73(1):8–15PubMedCrossRef
33.
Mehta SD (2012) Systemic review of randomized trials of treatment of male sexual partners for improved bacterial vaginosis outcomes in women. Sex Transm Dis 39(10):822–830PubMedCrossRef
34.
Martin J, Martin R (1971) Therapie genitaler Mykosen mit Dequavagyn. Dermatomykosen und Endomykosen 71(6):1–4
35.
Sobel JD (1985) Epidemiology and pathogenesis of recurrent vulvovaginal candidiasis. Am J Obstet Gynecol 152(7):924–935PubMedCrossRef
36.
Spinillo A, Capuzzo E, Acciano S, De Santolo A, Zara F (1999) Effect of antibiotic use on the prevalence of symptomatic vulvovaginal candidiasis. Am J Obstet Gynecol 180(1 Pt 1):14–17PubMedCrossRef
37.
Cook RL, Downs JS, Marrazzo J, Switzer GE, Tanriover O, Wiesenfeld H et al (2009) Preferred characteristics of vaginal microbicides in women with bacterial vaginosis. J Womens Health (Larchmt) 18(8):1163–1167CrossRef
38.
Eschenbach DA, Hillier SL, Critchlow C, Stevens C, DeRouen T, Holmes KK (1988) Diagnosis and clinical manifestations of bacterial vaginosis. Am J Obstet Gynecol 158(4):819–828PubMedCrossRef
39.
Hill JE, Goh SH, Money DM, Doyle M, Li A, Crosby WL et al (2005) Characterization of vaginal microflora of healthy, nonpregnant women by chaperonin-60 sequence-based methods. Am J Obstet Gynecol 193(3 Pt 1):682–692PubMedCrossRef
40.
Nagaraja P (2008) Antibiotic resistance of Gardnerella vaginalis in recurrent bacterial vaginosis. Indian J Med Microbiol 26(2):155–157PubMedCrossRef
41.
Forsum U, Larsson PG, Spiegel C (2008) Scoring vaginal fluid smears for diagnosis of bacterial vaginosis: need for quality specifications Letter to the Editor. APMIS 116(2):156–159PubMedCrossRef
42.
Goldstein EJ, Citron DM, Cherubin CE, Hillier SL (1993) Comparative susceptibility of the Bacteroides fragilis group species and other anaerobic bacteria to meropenem, imipenem, piperacillin, cefoxitin, ampicillin/sulbactam, clindamycin and metronidazole. J Antimicrob Chemother 31(3):363–372PubMedCrossRef
43.
Goldstein EJ, Citron DM, Merriam CV, Warren YA, Tyrrell KL, Fernandez HT (2002) In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother 46(12):3995–3996PubMedCentralPubMedCrossRef
44.
Ferrer J (2000) Vaginal candidosis: epidemiological and etiological factors. Int J Gynaecol Obstet 71(Suppl. 1):21–27CrossRef
45.
Recurrent Hay P, Vaginosis Bacterial (2000) Curr Infect Dis Rep 2(6):506–512CrossRef
46.
Sanchez S, Garcia PJ, Thomas KK, Catlin M, Holmes KK (2004) Intravaginal metronidazole gel versus metronidazole plus nystatin ovules for bacterial vaginosis: a randomized controlled trial. Am J Obstet Gynecol 191(6):1898–1906PubMedCrossRef
47.
48.
Mendling W (1995) Die Vulvovaginalkandidose Vaginose. Vaginitis und Zervizitis. Springer-Verlag, Berlin, pp 43–175CrossRef
49.
Cleveland A (2000) Vaginitis: finding the cause prevents treatment failure. Cleve Clin J Med 67(9):634PubMedCrossRef
50.
Tempera G, Bonfiglio G, Cammarata E, Corsello S, Cianci A (2004) Microbiological/clinical characteristics and validation of topical therapy with kanamycin in aerobic vaginitis: a pilot study. Int J Antimicrob Agents 24(1):85–88PubMedCrossRef
51.
Tempera G, Abbadessa G, Bonfiglio G, Cammarata E, Cianci A, Corsello S et al (2006) Topical kanamycin: an effective therapeutic option in aerobic vaginitis. J Chemother 18(4):409–414PubMedCrossRef
52.
Donders GGG, Van Buick B, Van de Walle P, Kaiser RR, Pohlig G, Gonser S et al (2010) Effect of lyophilised lactobacilli and 0.03 mg estriol (Gynoflor) on vaginitis and vaginosis with disrupted vaginal microflora: a multicenter, randomized, single-blind, active-controlled pilot study. Gynecol Obstet Invest 70:192–200CrossRef
53.
Austin MN, Beigi RH, Meyn LA, Hillier SL (2005) Microbiologic response to treatment of bacterial vaginosis with topical clindamycin or metronidazole. J Clin Microbiol 43(9):4492–4497PubMedCentralPubMedCrossRef
54.
55.
Ferris DG, Nyirjesy P, Sobel JD, Soper D, Pavletic A, Litaker MS (2002) Over-the-counter antifungal drug misuse associated with patient-diagnosed vulvovaginal candidiasis. Obstet Gynecol 99(3):419–425PubMedCrossRef
56.
Gajer P, Brotman RM, Bai G, Sakamoto J, Schutte UM, Zhong X et al (2012) Temporal dynamics of the human vaginal microbiota. Sci Transl Med 4(132):132ra52PubMedCentralPubMedCrossRef
57.
DeBacker E, Verhelst R, Verstraelen H, Alqumber MA, Burton JP, Tagg JR et al (2007) Quantitative determination by real-time PCR of four vaginal Lactobacillus species, Gardnerella vaginalis and Atopobium vaginae indicates an inverse relationship between L. gasseri and L. iners. BMC Microbiol 7:115CrossRef
58.
59.
Larsson PG, Stray-Pedersen B, Ryttig KR, Larsen S (2008) Human lactobacilli as supplementation of clindamycin to patients with bacterial vaginosis reduce the recurrence rate; a 6-month, double-blind, randomized, placebo-controlled study. BMC Womens Health 8:3PubMedCentralPubMedCrossRef
60.
Ozkinay E, Terek MC, Yayci M, Kaiser R, Grob P, Tuncay G (2005) The effectiveness of live lactobacilli in combination with low dose oestriol (Gynoflor) to restore the vaginal flora after treatment of vaginal infections. BJOG 112(2):234–240PubMedCrossRef
61.
Unzeitig V, Al Awad H (2006) New options of stabilization of disturbed vaginal environment balance. Prakticka Gynekologia 10(5):170–173
62.
Ya W, Reifer C, Miller LE (2010) Efficacy of vaginal probiotic capsules for recurrent bacterial vaginosis: a double-blind, randomized, placebo-controlled study. Am J Obstet Gynecol 203(2):120–126PubMedCrossRef
63.
Weissig V, Lasch J, Erdos G, Meyer HW, Rowe TC, Hughes J (1998) DQAsomes: a novel potential drug and gene delivery system made from dequalinium™. Pharm Res 15(2):334–337PubMedCrossRef
64.
Marghescu S (1975) Zur Behandlung bakterieller und mykotischer Hautinfektionen in den intertriginösen Räumen. Ther d Gegenw 114(3):427–434
65.
Merianos JJ (1991) Quaternary ammonium antimicrobial compounds. In: Block SS (ed) Disinfection, sterilization and preservation, 4 edn. pp 225–255
66.
Hugo WB, Frier M (1969) Mode of action of the antibacterial compound dequalinium acetate. Appl Microbiol 17(1):118–127PubMedCentralPubMed
67.
D’Auria FD, Simonetti G, Strippoli V (1989) Caratteristiche antimicrobiche di una tintura al dequalinio cloruro. Ann Ig 1:1227–1241PubMed
68.
Brauss FW, Rieth H (1974) Wirksamkeit von Dekamethylenaminochinaldiniumchlorid gegenüber pathogenen Mikroorganismen. Münch Med Wschr 35:1519–1520
69.
Della Casa V, Noll H, Gonser S, Grob P, Graf F, Pohlig G (2002) Antimicrobial activity of dequalinium chloride against leading germs of vaginal infections. Arzneim-Forsch/Drug Res 52(9):699–705
70.
Tischer M, Pradel G, Ohlsen K, Holzgrabe U (2012) Quaternary ammonium salts and their antimicrobial potential: targets or nonspecific interactions? Chem Med Chem 7(1):22–31PubMedCrossRef
71.
Cella JA, Eggenberger DN, Harriman LA, Harwood HJ (1952) The relation of structure and critical concentration to the bactericidal activity of quaternary ammonium salts. J Am Chem Soc 74:2061–2062CrossRef
72.
Cox WA (1965) Site of action of certain antibacterial heterocyclic quaternary ammonium compounds. Appl Microbiol 13(6):956–966PubMedCentralPubMed
73.
Paik SR, Kim DH, Chang CS (1996) Stimulation of an esterase activity of thrombin by dequalinium and its relationship with blood coagulation. J Biochem Mol Biol 29(3):225–229
74.
Babbs M, Collier HOJ, Austin WC, Potter MD, Taylor EP (1956) Salts of decamethylene-bis-4-aminoquinaldinium (Dequadin), a new antimicrobial agent. J Pharm Pharmacol 8:110–119PubMedCrossRef
75.
Collier HOJ, Cox WA, Huskinson PL, Robinson FA (1959) Further observations on the biological properties of dequalinium (Dequadyn) and hedaquinium (Teoquil). J Pharm Pharmacol 11:671–680PubMedCrossRef
76.
Cox WA, D’Arcy PF (1959) The anti-microbial activity of some mono and bis quaternary ammonium compounds. J Gen Microbiol 20(1):1–2CrossRef
77.
Cox WA, D’Arcy PF (1961) The activity of polymethylene-bis-4-aminoquinaldinium salts against Pityrosporum ovale and Candida albicans. J Pharm Pharmacol 13:34–38PubMedCrossRef
78.
D’Arcy PF, Cox WA, Hedge MJ, Wilkinson GR (1960) The effect of decamethylene-bis-4-aminoquinaldinium (dequalinium) salts on the growth of Pityrosporum ovale. J Soc Cosmet Chem 11:37–43
79.
Metzger WI, Jenkins CJJ (1961) Relative antimicrobial activity of topical chemotherapeutic compounds when tested, in vitro, in the presence and absence of human serum. Antibiot Chemother 11(5):335–339
80.
Lopes dos Santos SG, Grob P, Verstraelen H, Waser F, Vaneechoutte M (2012) Susceptibility testing of Atopobium vaginae for dequalinium chloride. BMC Res Notes 5:151CrossRef
81.
Turner RJ, Taylor DE, Weiner JH (1997) Expression of Escherichia coli TehA gives resistance to antiseptics and disinfectants similar to that conferred by multidrug resistance efflux pumps. Antimicrob Agents Chemother 41(2):440–444PubMedCentralPubMed
82.
Ali-Melkkila T, Kaila T, Kanto J (1989) Glycopyrrolate: pharmacokinetics and some pharmacodynamic findings. Acta Anaesthesiol Scand 33(6):513–517PubMedCrossRef
83.
Aquilonius SM, Hartvig P (1986) Clinical pharmacokinetics of cholinesterase inhibitors. Clin Pharmacokinet 11(3):236–249PubMedCrossRef
84.
Hallen B, Sundwall A (1987) Gastrointestinal transit rate-related absorption of emepronium: a study in mice. Pharmacol Toxicol 60(3):199–205PubMedCrossRef
85.
Liebmann B, Henke D, Spahn-Langguth H, Mutschler E (1991) Determination of the quaternary compound ciclotropium in human biological material after hydrolysis and derivatization with the fluorophor flunoxaprofen chloride. J Chromatogr 572(1–2):181–193PubMedCrossRef
86.
Noguchi H, Tokuma Y, Tamura Y (1983) Pharmacokinetics of prifinium bromide in healthy volunteers. Int J Clin Pharmacol Ther Toxicol 21(5):213–217PubMed
87.
Schladitz-Keil G, Spahn H, Mutschler E (1986) Determination of the bioavailability of the quaternary compound trospium chloride in man from urinary excretion data. Arzneimittelforschung 36(6):984–987PubMed
88.
Atlante G (1959) Un nuovo chemioterapico nella terapia delle vaginiti da trichomonas e da candida. Minerva Ginecol 11:588–591PubMed
89.
Bianco V, Minorchio E, Biraghi P, Stillo A, Como ML (1984) Impiego di una associazione di dequalinium, tirotricina e idrocortisone in lavanda nella terapia delle cervico vaginiti: studio clinico controllato. Ann Ost Gin Med Perin CV (4):260–266
90.
Crevoisier P, Serment H, Habersaat A (1970) Behandlung des Fluor vaginalis mit dem polyvalenten Kombinationspräparat Trichocid. Praxis 40:1401–1404
91.
Fauner A, Binder H (1974) Chemotherapie der Candida-Infektion in der Schwangerschaft. Ärztliche Praxis 26(74):3060
92.
Kolbe H (1972) Zur Behandlung des infektiösen vaginalen Fluors mit Dequavagyn. Ther d Gegenw 111(3):415–420
93.
Kucera H, Kupka S (1973) Zur Behandlung des infektiösen Fluors durch Dequaliniumchlorid und seiner Kombination mit verschiedenen Östriolkomponenten. Wien Med Wochenschr 123(46):683–685PubMed
94.
Lange K (1971) Medikamentöse Behandlung des infektiösen Fluors. Ärztliche Praxis 23(90):4153
95.
Levinson DR (1959) Dequalinium in the treatment of trichomoniasis in women. Practitioner 183:195–197PubMed
96.
Martin R (1971) Lokales Therapeutikum bei mykotischen und bakteriellen Kolpitiden gut bewährt. Medical Tribune 37:8
97.
Mühlbauer W (1972) Behandlung des infektiösen Fluors mit Dequavagyn. Therapiewoche 22(16):1414
98.
Rippmann ET (1974) Behandlung von Candida-, Trichomonaden- und unspezifischem Fluor. Ein Erfahrungsbericht. Frauenarzt 4:302–304
99.
Roddie TW (1958) Clinical evaluation of dequadin in the treatment of vaginal infections and infestations. Malayan Med J 13(2):171–172
100.
Tatra G (1972) Behandlung des infektiösen Fluors mit Dequavagyn. Münch Med Wschr 114(16):773–776PubMed
101.
Warnecke G (1976) Eriosept: Ein Vaginalschaumspray. Zur Therapie unspezifischer Vaginalinfektionen. Z Allg Med 52(22):1164–1166
102.
Dankovich DN, Gopchuk EN (2006) New opportunities in preparation of women with reproductive tracts microbiocenosis disorder for gynaecologic intervention. Women’s Health 2(26):1–4
103.
Demina TN, Pilipenko ON, Jotenko BA, Baksheeva OL (2005) The role of anti-microbial therapy in complex treatment of women with miscarriage. Women’s Reprod Health 3(23):99–102
104.
Grishchenko OV, Lahno IV, Dudko VL, Dudko LV, Stupak II, Storchak AV (2006) Clinical and prognostic aspects of bacterial vaginosis treatment in pregnant women. Women’s Health 4(28):69–72
105.
Grishchenko OV, Dudko VL, Lahno IV, Dudko LV, Storchak AV (2006) Clinical and prognostic aspects of mixed etiology vaginitis treatment. Women’s Reprod Health 2(27):8–10
106.
Tatarchuk TF, Zacharenko NF, Kosey NV, Suhorebraya EI (2006) Function of vaginal ecosystem in postoperative complications prophylaxis. Women’s Reprod Health 4(29):35–38
107.
Radzinsky VE, Ordiyants IM, Chetvertakova ES, Misuno OA (2011) Two Stage therapy for Vaginal Infections. Akusherstvo i Ginekologiia 5:78–81
108.
McCutchan JA, Ronald AR, Handsfield CL (1993) Evaluation of new anti-infective drugs for the treatment of vaginal infections. Eur Soc Clin Microbiol Infect Dis 15(Suppl 1):140–148
109.
Fowler RS (2007) Expansion of altered vaginal flora states in vaginitis to include a spectrum of microflora. J Reprod Med 52(2):93–99PubMed
Metadata
Title
Use of locally delivered dequalinium chloride in the treatment of vaginal infections: a review
Authors
Werner Mendling
Ernst Rainer Weissenbacher
Stefan Gerber
Valdas Prasauskas
Philipp Grob
Publication date
01-03-2016
Publisher
Springer Berlin Heidelberg
Published in
Archives of Gynecology and Obstetrics / Issue 3/2016
Print ISSN: 0932-0067
Electronic ISSN: 1432-0711
DOI
https://doi.org/10.1007/s00404-015-3914-8

Other articles of this Issue 3/2016

Archives of Gynecology and Obstetrics 3/2016 Go to the issue

Gynecologic Oncology

Neuroendocrine tumors in the ovary: histogenesis, pathologic differentiation, and clinical presentation

Gynecologic Endocrinology and Reproductive Medicine

The influence of AMH on IVF success

Maternal-Fetal Medicine

Predictive model for risk of cesarean section in pregnant women after induction of labor

Gynecologic Endocrinology and Reproductive Medicine

Effect of colchicine on polycystic ovary syndrome: an experimental study

General Gynecology

Low-dose isoflavone aglycone alleviates psychological symptoms of menopause in Japanese women: a randomized, double-blind, placebo-controlled study

Gynecologic Oncology

Clinical usefulness of the oral chemotherapy agent S-1 in heavily pre-treated patients with advanced or recurrent cervical cancer